title: Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
abstract: We report on 4 new cases of valvular heart disease in Parkinson's disease patients treated with the ergot derivative dopamine agonists pergolide and cabergoline. Noninflammatory fibrotic degeneration of cardiac valves has been reported to occur in patients with carcinoid syndrome and to occasionally complicate therapies with the anti-migraine ergot alkaloid ergotamine and methysergide and with the appetite suppressants fenfluramine and dexfenfluramine. In these cases, the pathogenesis is suspected to involve serotonin-mediated abnormal fibrogenesis by means of the 5-HT2B receptors, which are expressed in the fibroblasts of heart valves. Based on strikingly similar echocardiographic and histopathological features, we strongly suspect that ergot-derived dopamine agonists may cause a valvular heart disease nearly identical to that seen in those conditions. These cases add to a rapidly growing and worrying list of similar published reports, suggesting that we may well be facing a novel, yet unrecognized, complication of this class of agents, which are widely used not only in Parkinson's disease but also in restless legs syndrome and various common endocrine dysfunctions. Therefore, until more is known about the true prevalence of this side effect, we propose that an assessment of cardiac function be performed before and in the course of a long-term therapy with ergot derivative dopamine agonists.
authors.affiliation: Department of Neurology, University Hospital, Geneva, Switzerland.
authors.forename: Judit
authors.initials: J
authors.lastname: Horvath
authors.forename: Robin D
authors.initials: RD
authors.lastname: Fross
authors.forename: Galit
authors.initials: G
authors.lastname: Kleiner-Fisman
authors.forename: René
authors.initials: R
authors.lastname: Lerch
authors.forename: Hans
authors.initials: H
authors.lastname: Stalder
authors.forename: Suzanne
authors.initials: S
authors.lastname: Liaudat
authors.forename: William J
authors.initials: WJ
authors.lastname: Raskoff
authors.forename: Keith D
authors.initials: KD
authors.lastname: Flachsbart
authors.forename: Harry
authors.initials: H
authors.lastname: Rakowski
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Pache
authors.forename: Pierre R
authors.initials: PR
authors.lastname: Burkhard
authors.forename: Anthony E
authors.initials: AE
authors.lastname: Lang
mesh_terms: D000328:Adult; D000368:Aged; D000077465:Cabergoline; D002230:Carbidopa / Q000009:adverse effects* / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D004338:Drug Combinations; D017548:Echocardiography, Transesophageal / Q000295:instrumentation; D004873:Ergolines / Q000009:adverse effects* / Q000737:chemistry / Q000627:therapeutic use; D004876:Ergot Alkaloids / Q000032:analysis; D005260:Female; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000009:adverse effects* / Q000737:chemistry / Q000627:therapeutic use
chemical_list: D018491:Dopamine Agonists; D004338:Drug Combinations; D004873:Ergolines; D004876:Ergot Alkaloids; C009265:carbidopa, levodopa drug combination; D010479:Pergolide; D007980:Levodopa; D000077465:Cabergoline; D002230:Carbidopa